SIMULTANEOUS ESTIMATION OF LINAGLIPTIN AND RESVERATROL: DEVELOPMENT AND VALIDATION OF A UV-SPECTROSCOPIC STABILITY-INDICATING METHOD

Abstract

The simultaneous identification and detection of both medications is a challenge when a pharmaceutical product is formulated with a dual or combination drug delivery system. The most straightforward, precise, and dependable technique among the many that are accessible is UV spectroscopy. We have successfully developed and validated the UV Spectroscopy technique for concurrent estimation of Linagliptin (LGT) and Resveratrol (RSV). The percentage recovery of each drug at 50%, 100%, and 150% of the developed simultaneous equation was found to be 50.3% to 49.7%, 100.8% to 101.3%, and 150.3% to 149.7%for LGT and RSV, respectively. The percent relative standard deviation of the LGT and RSV mixture, the intra-day analysis was determined and found to be 1.221% at λ₁ and 1.162% at λ₂, respectively. In the inter-day study, % RSD was determined to be 1.136% at λ₁ and 1.393% atλ_2, respectively. Based on the data, we conclude that our approach is exact and accurate. Through the use of forced deterioration testing in a stability study, we have further verified our approach. Both of our medications were shown to breakdown in oxidative, alkaline, and acidic degradation conditions. Thermal and photolytic degradation studies were also conducted. Based on the findings, it was determined that our simultaneous estimation UV Spectroscopy approach is dependable and can open up new research avenues.